With a market cap of $114.8 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a biotechnology company specializing in ...

We recently published a list of 15 Best Stocks to Buy According to Jim Simons’ Renaissance Technologies In this article, we ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

The stock's fall snapped a four-day winning streak.

Vertex Pharmaceuticals (NASDAQ: VRTX), a leading drugmaker, is performing exceedingly well for the year -- or at least it was ...

Vertex Pharmaceuticals' (NASDAQ: VRTX) remarkable momentum came to a screeching halt this week. The big biotech stock had been up well over 20% year to date. The main bad news with Vertex's Q1 results ...

Buying $1000 In VRTX: If an investor had bought $1000 of VRTX stock 15 years ago, it would be worth $11,812.35 today based on ...

Vertex Pharmaceuticals (NASDAQ:VRTX) is set to release its earnings on Monday, May 5, 2025. For those trading based on events, analyzing historical stock behavior around earnings announcements can ...

VERTEX PHARMACEUTICALS INC (VRTX) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 75% based on the firm’s underlying fundamentals and the ...

At Stock Options Channel, our YieldBoost formula has looked up and down the VRTX options chain for the new June 2027 contracts and identified one put and one call contract of particular interest.

CRISPR Therapeutics stock is down more than 80% from the peak ... Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) missed Wall Street’s revenue expectations in Q1 CY2025 as sales rose ...